<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40101">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784523</url>
  </required_header>
  <id_info>
    <org_study_id>11179</org_study_id>
    <nct_id>NCT01784523</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients</brief_title>
  <official_title>A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>APS ACTION</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NY Community Trust Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center international study, our aim is to determine the effectiveness of HCQ
      for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients
      without systemic autoimmune diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized to receive HCQ or no treatment in addition to their standard regimen.  11 study
      visits and 10 phone visits over 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incident acute thrombosis</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>thrombosis incidence rate</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>In persistently aPL-positive patients with no other systemic autoimmune diseases, to determine:
The thrombosis incidence rate
The effect of Hydroxychloroquine on mortality rate
The effect of Hydroxychloroquine on aPL profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients randomized to standard treatment will not receive hydroxychloroquine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing &lt;60kg; and 400 mg daily (200 mg twice a day)for patients weighing &gt;60kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>plaquenil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent(at least 12 weeks apart)aPL-positivity within 12 months prior to the
             screening defined as:

               -  aCL IgG/M (&gt;40U,medium-to-high titer,and/or greater than the 99th
                  percentile)and/or

               -  aÎ²2GPI IgG/M(&gt;40U, medium-to-high titer, and/or greater than the 99th
                  percentile)and/or

               -  Positive LA test based on the International Society of Thrombosis &amp; Haematosis
                  Recommendations

        Selected Exclusion Criteria:

          -  History of thrombosis (arterial, venous, and/or biopsy proven  microthrombosis

          -  History of Transient Ischemic Attack Confirmed by a Neurologist

          -  SLE Diagnosis based on the ACR Classification Criteria &gt; 4/11

          -  Other Systemic Autoimmune Diseases diagnosed based on ACR Classification    Criteria

          -  Current Hydroxychloroquine or another antimalarial treatment (-3 months)

          -  Current warfarin treatment (-3 months)

          -  Current heparin therapy( -3 months)

          -  Current pregnancy

          -  History of Hydroxychloroquine eye toxicity

          -  History of Hydroxychloroquine allergy

          -  Known glucose-6-phosphate dehydrogenase deficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doruk Erkan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JoAnn Vega</last_name>
    <phone>212 774-2795</phone>
    <email>vegaj@hss.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Glendalee Ramon</last_name>
    <phone>212 774-2808</phone>
    <email>ramong@hss.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnn Vega</last_name>
      <phone>212-774-2795</phone>
      <email>vegaj@hss.edu</email>
    </contact>
    <contact_backup>
      <last_name>Glendalee Ramon</last_name>
      <phone>212 774-2808</phone>
      <email>ramong@hss.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Doruk Erkan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.apsaction.org</url>
    <description>APS ACTION</description>
  </link>
  <reference>
    <citation>Erkan D, Lockshin MD; APS ACTION members. APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus. 2012 Jun;21(7):695-8. doi: 10.1177/0961203312437810.</citation>
    <PMID>22635205</PMID>
  </reference>
  <reference>
    <citation>Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus. 2011 Feb;20(2):219-24. doi: 10.1177/0961203310395053.</citation>
    <PMID>21303838</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital for Special Surgery, New York</investigator_affiliation>
    <investigator_full_name>Doruk Erkan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>antiphospholipid autoantibodies</keyword>
  <keyword>antiphospholipid positive</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
